SAN FRANCISCO – Qardio, Inc., announced today it has received the approval from Australia’s Therapeutic Goods Administration (TGA) for QardioCore, its revolutionary ECG monitor.
“We are delighted to take QardioCore to the Australian market. QardioCore brings ease of use and convenience to patients and – in conjunction with QardioMD – powerful features and a new level of efficiency to medical professionals,” says Alexis Zervoglos, Chief Business Officer of Qardio.
The device is the first wearable medical electrocardiogram (ECG/EKG) monitor allowing users to proactively look after their heart health long-term, all without the need for wires or patches. Packed with proprietary sensor technology, QardioCore records more than 20 million data points a day, streaming the user’s live medical-grade health data to their smartphones.
QardioCore pairs with the free Qardio App for iOS and works with iPhone, iPad and Apple watch and integrates with Apple Health. QardioCore is worn as a chest strap and seamlessly records continuous ECG, heart rate, heart rate variability, respiratory rate, temperature and activity data. The data can then be easily and automatically shared with medical professionals.
QardioCore works alongside Qardio’s other products, including QardioArm, a smart blood pressure monitor, QardioBase 2, a wireless scale and body analyzer and QardioMD, a patient data dashboard for doctors.
Customers in Australia can now purchase the device through authorized medical distributors or on www.qardio.com for shipment starting January 2nd. QardioCore is priced at AUD $699.99. To order QardioCore, go to https://store-au.qardio.com/.